Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | SLO | ENG

Naslov:Novosti v dopolnilnem zdravljenju HER2-pozitivnega raka dojke
Avtorji:Matos, Erika (Avtor)
Jezik:Slovenski jezik
Tipologija:1.04 - Strokovni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Leto izida:2008
UDK:616-006
ISSN pri članku:1408-1741
OceCobissID:65324032 Povezava se odpre v novem oknu
URN:URN:NBN:SI:doc-BRZ6IBU5
COBISS_ID:620411 Povezava se odpre v novem oknu
Število ogledov:1450
Število prenosov:309
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (377,95 KB)
 
Nadgradivo:Onkologija
Onkološki inštitut
 
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
Avtorske pravice:by Authors
:
  
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.


Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:31.08.2018

Sekundarni jezik

Jezik:Angleški jezik
Naslov:Update on Adjuvant Treatment of HER2-Positive Breast Cancer
Povzetek:Although trastuzumab-based regimens have improved both systemic control and overall survival in the patients with HER2-positive breast cancer, in some of these patients, tumor progression occurs despite trastuzumab treatment. New target therapies are searched for these patients. The most promising and, in terms of clinical use, the most developed is lapatinib, a small molecule, tyrosine-kinase inhibitor that targets not only HER2- but also HER1-receptor. It is already used for treating the HER2-positive metastatic breast cancer patients after failure of trastuzumab therapy, but its effectiveness in adjuvant therapy has not been proven yet. ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization) is a randomized phase-three multi-center study of adjuvant lapatinib, trastuzumab, their sequence and their combination in the patients with HER2 positive primary breast cancer.

Arhiv

niGradiv

Nazaj